80年代后期,对中晚期肝癌广泛地开展了动脉内药物灌注(TAI)或栓塞化疗(TACE),现已被公认介入治疗是最有效的保守疗法,取得了较好的成绩,TACE 的1、3年生存率在44%～68%和12%～30%之间。而单纯的 TAI的疗效较差,1年生存率为8.8%～20.5%,现已很少单独使用。一、小肝癌的介入治疗小肝癌是指<3 cm 的肿瘤,目前倾向于2cm 以下的病灶。其传统治疗方法是肝叶切除,Farmer 综合文献报道1、3、5年的生存率分别为33%～80%、20%～50%、12%～39%。近年 In the late 1980s, intra-arterial drug infusion (TAI) or embolization chemotherapy (TACE) was widely performed for advanced and intermediate liver cancer. It has been recognized that interventional treatment is the most effective conservative treatment and has achieved good results. TACE 1. The 3-year survival rate is between 44% and 68% and between 12% and 30%. However, the efficacy of simple TAI is poor, and the one-year survival rate is 8.8% to 20.5%, and it is rarely used alone. First, interventional treatment of small hepatocellular carcinoma Small hepatocellular carcinoma refers to <3 cm tumors, currently tend to 2cm below the lesion. The traditional method of treatment is liver lobectomy. The comprehensive literature reports from Farmer reported that the 1-, 3-, and 5-year survival rates were 33% to 80%, 20% to 50%, and 12% to 39%, respectively. in recent years